Rank |
Status |
Study |
1 |
Not yet recruiting
|
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
Conditions: |
Kawasaki Disease; Coronary Aneurysm |
Interventions: |
Drug: Doxycycline; Drug: Standard care |
Outcome Measures: |
Coronary artery diameter change; Assess the change in MMP-9 level; Assess a change in TIMP level |
|
2 |
Unknown †
|
Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population
Condition: |
Malignant Pleural Effusion |
Interventions: |
Drug: Doxycycline; Other: normal saline |
Outcome Measures: |
Time to pleurodesis; Pleurodesis rates at 90 days post Pleurx insertion; Number of participants with adverse events; Effects on pulmonary function |
|
3 |
Unknown †
|
Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
Condition: |
Transthyretin Amyloidosis |
Intervention: |
Drug: Doxycycline + Tauroursodeoxycholic acid |
Outcome Measures: |
Response rate to Doxycycline + tauroursodeoxycholic acid treatment; Number of patients experiencing treatment-emergent adverse events; Change in quality of life; Doxycycline pharmacokinetics (PK); response in autonomic dysfunction, sensory-motor peripheral neuropathy and visceral organ involvement; neurologic response; Incidence of patients discontinuing from the study because of clinical or laboratory adverse events |
|
4 |
Recruiting
|
Doxycycline in Therapy of Erythema Migrans
Condition: |
Lyme Borreliosis |
Intervention: |
Drug: Doxycycline |
Outcome Measures: |
Comparing of objective sequelae and post-treatment subjective symptoms in three groups of erythema migrans patients treated with Doxycycline: with no accompanying symptoms, with mild and with severe symptoms at the beginning.; Comparison of subjective symptoms between erythema migrans patients treated with Doxycycline and control subjects without a history of Lyme borreliosis. |
|
5 |
Recruiting
|
Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer
Condition: |
Pain |
Intervention: |
Drug: Doxycycline |
Outcome Measures: |
palliative benefit; changes to bone formation markers |
|
6 |
Recruiting
|
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
Conditions: |
Non-ischemic Cardiomyopathy; Systolic Heart Failure (NYHA II-III) |
Interventions: |
Drug: Doxycycline; Drug: placebo |
Outcome Measure: |
Peak aerobic exercise capacity |
|
7 |
Recruiting
|
Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study
Conditions: |
Chronic Pelvic Pain Syndrome; Bladder Pain Syndrome |
Interventions: |
Drug: Doxycycline; Drug: placebo |
Outcome Measures: |
Change in the O'Leary-Sant IC symptom and problem index total score from baseline; Changes of patient reported pain, urgency, frequency, functional bladder capacity documented in 72-hour pain and bladder diary, completed during the 3 days before the particular follow-up visit.; Changes in sexual function assessed by the Female Sexual Function Index (FSFI) at the time of the particular follow-up visit |
|
8 |
Unknown †
|
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Condition: |
Mucositis |
Intervention: |
Drug: Doxycycline hyclate |
Outcome Measures: |
Complete response; Partial resolution of oral lesions, incidence of infections and mortality. |
|
9 |
Unknown †
|
Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
Conditions: |
Chronic Obstructive Pulmonary Disease; Inflammation; Pulmonary Emphysema |
Interventions: |
Drug: Doxycycline; Drug: Placebo |
Outcome Measures: |
myeloperoxidase in induced sputum; MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum.; Lung function (FEV1); Symptom scores |
|
10 |
Recruiting
|
Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
Condition: |
Thyroid Associated Opthalmopathies |
Interventions: |
Drug: Prednisone+placebo of Doxycycline; Drug: Doxycycline+placebo of Prednisone |
Outcome Measures: |
Overall treatment response; • Health related quality of life questionnaires (GO-QoL); • Safety and tolerability as assessed by adverse events, vital signs; • Quantitative changes of rectus diameter measured by MRI scan; Relapse |
|
11 |
Recruiting
|
Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome
Conditions: |
Polycystic Ovarian Syndrome (PCOS); Irregular Menstrual Cycles; Androgen Excess |
Interventions: |
Drug: Doxycycline; Drug: Sugar Pill |
Outcome Measures: |
Assess the effectiveness of daily Doxycycline use in the primary outcome of reduction of serum testosterone and in women with PCOS during and beyond the treatment course.; Assess the effectiveness of daily Doxycycline use in the secondary outcome of restoring ovulation in women with PCOS during and beyond the treatment course. |
|
12 |
Unknown †
|
Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis
Condition: |
Suspected Early Lyme Neuroborreliosis |
Interventions: |
Drug: Doxycycline; Drug: ceftriaxone |
Outcome Measure: |
Objective sequelae and post-treatment subjective symptoms in patients treated for suspected early Lyme neuroborreliosis with normal CSF cell count with Doxycycline or ceftriaxone for 14 days. |
|
13 |
Recruiting
|
Doxycycline, Temozolomide and Ipilimumab in Melanoma
Condition: |
Melanoma |
Interventions: |
Drug: Doxycycline; Drug: Ipilimumab; Drug: Temozolomide |
Outcome Measure: |
Overall Response Rate |
|
14 |
Unknown †
|
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial MMPs
Condition: |
Breakthrough Bleeding |
Intervention: |
Drug: Doxycycline |
Outcome Measures: |
Determine the effect of combined oral contraceptives on endometrial MMP expression.; Determine the effect of sub-antimicrobial Doxycycline on MMP expression and activity in continuous oral contraceptive users. |
|
15 |
Recruiting
|
Antibiotic Treatment of Multiple Erythema Migrans
Condition: |
Multiple Erythema Migrans |
Interventions: |
Drug: ceftriaxone; Drug: Doxycycline; Other: erythema migrans patients treated with Doxycycline |
Outcome Measures: |
Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or Doxycycline for 15 days.; Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.; Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment. |
|
16 |
Recruiting
|
A Phase II Study of Doxycycline in Relapsed NHL
Conditions: |
Adult Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma Recurrent; Lymphoma, Follicular; Marginal Zone B-Cell Lymphoma; Malignant Lymphoma - Lymphoplasmacytic; Waldenstrom Macroglobulinemia; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia (CLL); T-Cell Lymphoma |
Intervention: |
Drug: Doxycycline |
Outcome Measures: |
Overall response rate; Progression free survival |
|
17 |
Unknown †
|
The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne
Conditions: |
Acne; Inflammation |
Intervention: |
Drug: Doxycycline |
Outcome Measure: |
|
|
18 |
Recruiting
|
Doxycycline for COPD in HIV-Infected Patients
Conditions: |
HIV; Chronic Obstructive Pulmonary Disease (COPD); Emphysema |
Intervention: |
Drug: Doxycycline |
Outcome Measures: |
Safety and tolerability; Larger phase II clinical trial |
|
19 |
Recruiting
|
Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
Conditions: |
Amyloidosis; Heart (Manifestation); Senile Cardiac Amyloidosis |
Intervention: |
Drug: Tauroursodeoxycholic Acid and Doxycycline |
Outcome Measures: |
The rate of progression of transthyretin cardiac amyloidosis, as measured by changes in strain echocardiography, in a group of patients taking a combination of Doxycycline and TUDCA.; Number of patients with adverse events to the medications over the period of therapy (18 months); To evaluate general and health related quality of life (QoL) in SSA and ATTR subjects. |
|
20 |
Recruiting
|
Management of Etonogestrel Subdermal Implant-related Bleeding
Condition: |
ESI-related Bleeding |
Interventions: |
Drug: Doxycycline; Drug: Placebo |
Outcome Measures: |
Efficacy and safety of Doxycycline compared to placebo for unacceptable bleeding; Patient Satisfaction; Method Continuation rate |
|